



P&T Committee Review Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Review
Location:	Zoom Conference: https://magellanhealth.zoom.us/webinar/register/WN_ulhYwfRwQYCIUYHNE45QOg
Date:	April 26, 2024
Members Present:	▪ Ben Orlando, RPh ▪ Dr. Charles C. Coleman ▪ Dr. Jill Comeau ▪ J. Scott Black ▪ Julio Figueroa ▪ Shantel Herbert-Magee
LDH Staff Present:	▪ Katrina Johnson ▪ Sue Fontenot, RPh ▪ ·HALEY WILLIAMS ▪ ·Kolynda Parker ▪ Rachel Broussard
Contractors Present:	▪ Hind Douiki, PharmD, Magellan Medicaid Administration ▪ Kara Delaney, PharmD, Magellan Medicaid Administration
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Mr. Ben Orlando, Chairman, called the meeting to order at or around 9:37 a.m.

Parliamentary Business

- A. **Introduction of Members/Roll Call.** Mr. Orlando asked P&T Committee members, LDH staff, and Magellan staff to introduce themselves.
- B. **Approval of November 4, 2022 Meeting Minutes.** Mr. Orlando indicated the members cannot vote on approval of the Minutes due to not having quorum.

P & T Committee Review Virtual Process

Ms. Douiki indicated this meeting will be held in-person and virtually. Due to lack of quorum, there will be no voting or making motions; only discussions will be made, which the Secretary will take into consideration in order to make final decisions that will be implemented on 7/1/2024.

Ms. Douiki also provided an overview of the virtual part of the P&T committee meeting. She indicated that the virtual meeting is technologically set up so that only panelists (P&T committee members, LDH staff, and Magellan staff) will be able to speak. Members of the public will be able to listen and only speak when allowed by the Chair and when it is their turn to provide public testimony.

Ethics

Ms. Williams presented the code of governmental ethics for the P&T committee members. She indicated they set forth objective standards of conduct to protect public confidence in the integrity of government by ensuring public servants remain independent and impartial, decisions and policy are made in the proper channel, and public positions are not used for private gain.

Reports

Ms. Fontenot informed the P&T Committee members that LA currently participates in the TOP\$ pool to maximize supplemental rebates. She indicated the 2023 PDL recommendations have been sent to the committee by email. On May 1, 2019, the state implemented a single preferred drug list for administrative simplification and standardized the PDL across all MCOs and the FFS program. Also, through the single PDL program, the state can collect supplemental rebates by contracted medications dispensed to all Medicaid members, rather than to FFS beneficiaries only. The number of reviewed PDL classes for Louisiana Medicaid has increased over time to 135 due to MCO input. For fourth quarter 2023, the MCOs were 97.5 percent compliant with the preferred drugs on the single PDL. On July 15th, 2019, the state executed its hepatitis C subscription model to help eradicate this disease in Louisiana while using a cost-effective initiative. The state entered into a five-year supplemental rebate agreement with Asegua that caps gross annual expenditures for one contracted hepatitis C medication. This model allows unlimited access after the cap is met. The five-year contract is up this the end of June 2024. However, LDH is excited to announce the continuation of the hepatitis C subscription model, a partnership with Asegua, for one additional year, from July 2024 to June 2025.

Introduction - Undersecretary Michael Harrington

Mr. Harrington indicated that he would like to move to a generic PDL as of 7/1/2024 due to access in rural areas of LA. And due to the cost of brand name drug inventory. He also provided information about his professional background.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Ms. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She presented information about clinical and financial components of the recommendation process. She also summarized the supplemental rebate process. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates...etc. The committee members should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Dave Miley	Teva	Ajovy
Paul Miner	Pfizer	Genotropin
Alexandra Laland	Eli Lilly	Mounjaro
Kathy Gamamona	Novo Nordisk	Rybelsus
Brian Wilson	Genentech	Ocrevus
Evan Pence	Indivior	Sublocade and Opvee
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Acne Agents, Topical

Recommendations for the PDL are:

- CLINDAMYCIN / BENZOYL PEROXIDE (BENZACLIN) (TOPICAL)
- CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)
- CLINDAMYCIN PHOSPHATE GEL (TOPICAL)
- CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)
- CLINDAMYCIN PHOSPHATE MED. SWAB (TOPICAL)
- CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)
- ERYTHROMYCIN GEL (AG) (TOPICAL)

- ERYTHROMYCIN GEL (TOPICAL)
- ERYTHROMYCIN SOLUTION (TOPICAL)
- RETIN-A CREAM (TOPICAL)
- TRETINOIN CREAM (TOPICAL)

There were no further discussions made by the committee about this class.

Analgesics Narcotics, Long

Recommendations for the PDL are:

- BUPRENORPHINE (TRANSDERM)
- BUTRANS (TRANSDERM)
- FENTANYL (TRANSDERM)
- MORPHINE ER TABLET (ORAL)
- XTAMPZA ER (ORAL)

There were no further discussions made by the committee about this class.

Analgesics Narcotics, Short

Recommendations for the PDL are:

- APAP / CODEINE ELIXIR (ORAL)
- APAP / CODEINE TABLET (ORAL)
- HYDROCODONE / APAP SOLUTION (ORAL)
- HYDROCODONE / APAP TABLET (ORAL)
- HYDROMORPHONE TABLET (ORAL)
- MORPHINE DISP SYRIN (ORAL)
- MORPHINE IR TABLET (ORAL)
- OXYCODONE / APAP TABLET (ORAL)
- OXYCODONE TABLET (ORAL)
- TRAMADOL (ORAL)
- TRAMADOL / APAP (ORAL)

There were no further discussions made by the committee about this class.

Androgenic Agents

Recommendations for the PDL are:

- ANDRODERM (TRANSDERM)
- TESTOSTERONE GEL (AG) (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL PACKET (AG) (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL PUMP (AG) (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL PUMP (ANDROGEL) (TRANSDERM)
- TESTOSTERONE GEL PUMP (VOGELXO) (TRANSDERM)

There were no further discussions made by the committee about this class.

Angiotensin Modulator Combinations

Recommendations for the PDL are:

- AMLODIPINE / BENAZEPRIL (ORAL)
- AMLODIPINE / OLMESARTAN (AG) (ORAL)
- AMLODIPINE / OLMESARTAN (ORAL)
- AMLODIPINE / VALSARTAN (ORAL)

There were no further discussions made by the committee about this class.

Angiotensin Modulators

Recommendations for the PDL are:

- BENAZEPRIL (ORAL)
- BENAZEPRIL HCTZ (ORAL)
- ENALAPRIL (ORAL)
- ENALAPRIL HCTZ (ORAL)
- ENALAPRIL SOLUTION (AG) (ORAL)
- ENALAPRIL SOLUTION (ORAL)
- ENTRESTO (ORAL)
- FOSINOPRIL (ORAL)
- FOSINOPRIL HCTZ (ORAL)
- IRBESARTAN (ORAL)
- IRBESARTAN HCTZ (ORAL)
- LISINOPRIL (ORAL)
- LISINOPRIL HCTZ (ORAL)
- LOSARTAN (ORAL)
- LOSARTAN HCTZ (ORAL)
- OLMESARTAN (AG) (ORAL)
- OLMESARTAN (ORAL)
- OLMESARTAN HCTZ (AG) (ORAL)
- OLMESARTAN HCTZ (ORAL)
- QUINAPRIL (ORAL)
- QUINAPRIL HCTZ (AG) (ORAL)
- QUINAPRIL HCTZ (ORAL)
- RAMIPRIL (ORAL)
- VALSARTAN (ORAL)
- VALSARTAN HCTZ (ORAL)

There were no further discussions made by the committee about this class.

Antibiotics, GI

Recommendations for the PDL are:

- METRONIDAZOLE TABLET (ORAL)
- NEOMYCIN (ORAL)
- TINIDAZOLE (ORAL)
- VANCOMYCIN CAPSULE (AG) (ORAL)
- VANCOMYCIN CAPSULE (ORAL)

There were no further discussions made by the committee about this class.

Antibiotics, Inhaled

Recommendations for the PDL are:

- BETHKIS (INHALATION)
- TOBRAMYCIN (TOBI) (INHALATION)
- TOBRAMYCIN (BETHKIS) (AG) (INHALATION)
- TOBRAMYCIN (BETHKIS) (INHALATION)

There were no further discussions made by the committee about this class.

Antibiotics, Topical

Recommendations for the PDL are:

- MUPIROCIN OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Antibiotics, Vaginal

Recommendations for the PDL are:

- CLINDAMYCIN (VAGINAL)
- METRONIDAZOLE (VAGINAL)
- NUVESSA (VAGINAL)

There were no further discussions made by the committee about this class.

Anticoagulants

Recommendations for the PDL are:

- DABIGATRAN (ORAL)
- ELIQUIS (ORAL)
- ELIQUIS DOSE PACK (ORAL)

- ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS)
- ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS)
- ENOXAPARIN SYRINGE (AG) (SUBCUTANE.)
- ENOXAPARIN SYRINGE (SUBCUTANE.)
- PRADAXA (ORAL)
- WARFARIN (ORAL)
- XARELTO (ORAL)
- XARELTO DOSE PACK (ORAL)

There were no further discussions made by the committee about this class.

Antivertigo/Antiemetic Agents

Recommendations for the PDL are:

- MECLIZINE (AG) (ORAL)
- MECLIZINE (ORAL)
- METOCLOPRAMIDE SOLUTION (ORAL)
- METOCLOPRAMIDE TABLET (ORAL)
- METOCLOPRAMIDE VIAL (INJECTION)
- ONDANSETRON ODT (ORAL)
- ONDANSETRON SOLUTION (ORAL)
- ONDANSETRON TABLETS (ORAL)
- ONDANSETRON VIAL (INTRAVEN)
- PROCHLORPERAZINE (ORAL)
- PROMETHAZINE (RECTAL)
- PROMETHAZINE AMPUL (INJECTION)
- PROMETHAZINE SYRUP (ORAL)
- PROMETHAZINE TABLET (ORAL)
- PROMETHAZINE VIAL (INJECTION)
- SCOPOLAMINE (TRANSDERM)

There were no further discussions made by the committee about this class.

Antifungals, Oral

Recommendations for the PDL are:

- CLOTRIMAZOLE (MUCOUS MEM)
- FLUCONAZOLE SUSPENSION (ORAL)
- FLUCONAZOLE TABLET (ORAL)
- GRISEOFULVIN SUSPENSION (ORAL)
- NYSTATIN SUSPENSION (ORAL)
- NYSTATIN TABLET (ORAL)
- TERBINAFINE (ORAL)

There were no further discussions made by the committee about this class.

Antifungals, Topical

Recommendations for the PDL are:

- CLOTRIMAZOLE CREAM RX (TOPICAL)
- CLOTRIMAZOLE SOLUTION RX (TOPICAL)
- CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)
- KETOCONAZOLE CREAM (TOPICAL)
- KETOCONAZOLE SHAMPOO (TOPICAL)
- NYSTATIN CREAM (TOPICAL)
- NYSTATIN OINT (TOPICAL)
- NYSTATIN POWDER (TOPICAL)
- NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)
- NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)

There were no further discussions made by the committee about this class.

Antimigraine Agents, Other

Recommendations for the PDL are:

- AIMOVIG (SUBCUTANEOUS)
- AJOVY AUTOINJECTOR (SUBCUTANEOUS)
- AJOVY AUTOINJECTOR 3-PK (SUBCUTANEOUS)
- AJOVY (SUBCUTANEOUS)
- EMGALITY PEN (SUBCUTANEOUS)
- EMGALITY SYRINGE 120 MG (SUBCUTANEOUS)
- NURTEC ODT (ORAL)
- QULIPTA (ORAL)
- UBRELVY (ORAL)

There were no further discussions made by the committee about this class.

Antimigraine Agents, Triptans

Recommendations for the PDL are:

- IMITREX (NASAL)
- RIZATRIPTAN ODT (ORAL)
- RIZATRIPTAN TABLET (ORAL)
- SUMATRIPTAN (AG) (NASAL)
- SUMATRIPTAN (NASAL)
- SUMATRIPTAN (ORAL)
- SUMATRIPTAN VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Antiparasitics, Topical

Recommendations for the PDL are:

- NATROBA (TOPICAL)
- PERMETHRIN CREAM (TOPICAL)
- SPINOSAD (TOPICAL)

There were no further discussions made by the committee about this class.

Antivirals, Oral

Recommendations for the PDL are:

- ACYCLOVIR CAPSULE (ORAL)
- ACYCLOVIR SUSPENSION (ORAL)
- ACYCLOVIR TABLET (ORAL)
- FAMCICLOVIR (ORAL)
- OSELTAMIVIR CAPSULE (ORAL)
- OSELTAMIVIR SUSPENSION (ORAL)
- VALACYCLOVIR (ORAL)

There were no further discussions made by the committee about this class.

Antivirals, Topical

Recommendations for the PDL are:

- ACYCLOVIR OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Beta Blockers

Recommendations for the PDL are:

- ACEBUTOLOL (ORAL)
- ATENOLOL (ORAL)
- ATENOLOL / CHLORTHALIDONE (ORAL)
- BISOPROLOL (ORAL)
- BISOPROLOL HCTZ (ORAL)
- BYSTOLIC (ORAL)
- CARVEDILOL (ORAL)
- HEMANGEOL (ORAL)
- LABETALOL (ORAL)
- METOPROLOL (ORAL)
- METOPROLOL XL (AG) (ORAL)
- METOPROLOL XL (ORAL)
- NADOLOL (ORAL)

- NEBIVOLOL (ORAL)
- PROPRANOLOL ER (AG) (ORAL)
- PROPRANOLOL ER (ORAL)
- PROPRANOLOL SOLUTION (ORAL)
- PROPRANOLOL TABLET (ORAL)
- SOTALOL (ORAL)

There were no further discussions made by the committee about this class.

Bladder Relaxant Preparations

Recommendations for the PDL are:

- FESOTERODINE ER (ORAL)
- MYRBETRIQ (ORAL)
- OXYBUTYNIN ER (ORAL)
- OXYBUTYNIN SYRUP (ORAL)
- OXYBUTYNIN TABLET (ORAL)
- SOLIFENACIN (ORAL)

There were no further discussions made by the committee about this class.

Bone Resorption Suppression and Related Agents

Recommendations for the PDL are:

- ALENDRONATE TABLETS (ORAL)
- CALCITONIN SALMON (NASAL)
- IBANDRONATE TABLETS (ORAL)
- RALOXIFENE (ORAL)

There were no further discussions made by the committee about this class.

BPH Treatments

Recommendations for the PDL are:

- ALFUZOSIN (ORAL)
- DOXAZOSIN (AG) (ORAL)
- DOXAZOSIN (ORAL)
- DUTASTERIDE (ORAL)
- FINASTERIDE (ORAL)
- TAMSULOSIN (ORAL)
- TERAZOSIN (ORAL)

There were no further discussions made by the committee about this class.

Calcium Channel Blockers

Recommendations for the PDL are:

- AMLODIPINE (ORAL)
- DILTIAZEM CAPSULE ER (ORAL)
- DILTIAZEM TABLET (ORAL)
- FELODIPINE ER (ORAL)
- NIFEDIPINE ER (ORAL)
- NIFEDIPINE IR (ORAL)
- VERAPAMIL TABLET (ORAL)
- VERAPAMIL TABLET ER (ORAL)

There were no further discussions made by the committee about this class.

Cephalosporins and Related Antibiotics

Recommendations for the PDL are:

- AMOXICILLIN/CLAV SUSPENSION (AG) (ORAL)
- AMOXICILLIN/CLAV SUSPENSION (ORAL)
- AMOXICILLIN/CLAV TABLET (AG) (ORAL)
- AMOXICILLIN/CLAV TABLET (ORAL)
- CEFADROXIL CAPSULE (ORAL)
- CEFDINIR CAPSULE (ORAL)
- CEFDINIR SUSPENSION (ORAL)
- CEFPROZIL SUSPENSION (ORAL)
- CEFPROZIL TABLET (ORAL)
- CEFUROXIME TABLET (ORAL)
- CEPHALEXIN CAPSULE (ORAL)
- CEPHALEXIN SUSPENSION (ORAL)

There were no further discussions made by the committee about this class.

Cystic Fibrosis

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Fluoroquinolones, Oral

Recommendations for the PDL are:

- CIPROFLOXACIN TABLET (ORAL)
- LEVOFLOXACIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

GI Motility, Chronic

Recommendations for the PDL are:

- AMITIZA (ORAL)
- LINZESS (ORAL)
- LUBIPROSTONE (AG) (ORAL)
- LUBIPROSTONE (ORAL)
- MOVANTIK (ORAL)
- RELISTOR SYRINGE (SUBCUTANE.)
- RELISTOR VIAL (SUBCUTANE.)
- TRULANCE (ORAL)

There were no further discussions made by the committee about this class.

Glucagon Agents

Recommendations for the PDL are:

- BAQSIMI (NASAL)
- GLUCAGON (INJECTION)
- GLUCAGON EMERGENCY KIT (LILLY) (INJECTION)
- ZEGALOGUE AUTOINJECTOR (SUBCUTANEOUS)

There were no further discussions made by the committee about this class.

Growth Factors

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Growth Hormone

Recommendations for the PDL are:

- GENOTROPIN CARTRIDGE (INJECTION)
- GENOTROPIN DISP SYRIN (INJECTION)
- NORDITROPIN PEN (INJECTION)

There were no further discussions made by the committee about this class.

H. Pylori Treatment

Recommendations for the PDL are:

- BISMUTH/METRONID/TETRACYCLINE CAPSULE (ORAL)
- PYLERA (ORAL)

There were no further discussions made by the committee about this class.

HAE Treatments

Recommendations for the PDL are:

- HAEGARDA (SUB-Q)
- ICATIBANT (SUBCUT)

There were no further discussions made by the committee about this class.

Hepatitis C Agents

Recommendations for the PDL are:

- PEGASYS SYRINGE (SUB-Q)
- PEGASYS VIAL (SUBCUTANE.)
- RIBAVIRIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

HIV/AIDS

Recommendations for the PDL are:

- All of the drugs in this class are recommended preferred

There were no further discussions made by the committee about this class.

Hypoglycemics, Alpha-Glucosidase Inhibitors

Recommendations for the PDL are:

- ACARBOSE (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Incretin Mimetics/Enhancers

Recommendations for the PDL are:

- BYETTA PENS (SUBCUTANE.)

- JANUMET (ORAL)
- JANUMET XR (ORAL)
- JANUVIA (ORAL)
- JENTADUETO (ORAL)
- OZEMPIC (SUBCUTANE.)
- RYBELSUS (ORAL)
- TRADJENTA (ORAL)
- TRULICITY (SUBCUTANE.)
- VICTOZA (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Hypoglycemics, Insulin and Related Agents

Recommendations for the PDL are:

- APIDRA SOLOSTAR PEN (SUBCUTANE.)
- APIDRA VIAL (SUBCUTANE.)
- HUMALOG CARTRIDGE (SUBCUTANE.)
- HUMALOG JUNIOR KWIKPEN (SUBCUTANE.)
- HUMALOG MIX PEN (SUBCUTANE.)
- HUMALOG MIX VIAL (SUBCUTANE.)
- HUMALOG PEN (SUBCUTANE.)
- HUMALOG VIAL (SUBCUTANE.)
- HUMULIN 500 U/M PEN (SUBCUTANE.)
- HUMULIN 500 U/M VIAL (SUBCUTANE.)
- HUMULIN 70/30 PEN OTC (SUBCUTANE.)
- HUMULIN 70/30 VIAL OTC (SUBCUTANE.)
- HUMULIN VIAL OTC (SUBCUTANE.)
- INSULIN ASPART CARTRIDGE (AG) (SUBCUTANE.)
- INSULIN ASPART PEN (AG) (SUBCUTANE.)
- INSULIN ASPART VIAL (AG) (SUBCUTANE.)
- INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS)
- INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANE.)
- INSULIN GLARGINE PEN (SUBCUTANE.)
- INSULIN GLARGINE VIAL (SUBCUTANE.)
- INSULIN LISPRO JUNIOR KWIKPEN (AG) (SUBCUTANE.)
- INSULIN LISPRO PEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO VIAL (AG) (SUBCUTANEOUS)
- LANTUS SOLOSTAR PEN (SUBCUTANE.)
- LANTUS VIAL (SUBCUTANE.)
- NOVOLOG CARTRIDGE (SUBCUTANE.)
- NOVOLOG MIX PEN (SUBCUTANE.)

- NOVOLOG MIX VIAL (SUBCUTANE.)
- NOVOLOG PEN (SUBCUTANE.)
- NOVOLOG VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Hypoglycemics, Meglitinides

Recommendations for the PDL are:

- NATEGLINIDE (ORAL)
- REPAGLINIDE (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Metformins

Recommendations for the PDL are:

- GLIPIZIDE-METFORMIN (ORAL)
- GLYBURIDE-METFORMIN (ORAL)
- METFORMIN (ORAL)
- METFORMIN ER (GLUCOPHAGE XR) (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, SGLT2

Recommendations for the PDL are:

- DAPAGLIFLOZIN (AG) (ORAL)
- DAPAGLIFLOZIN-METFORMIN ER (AG) (ORAL)
- FARXIGA (ORAL)
- INVOKAMET (ORA
- INVOKANA (ORAL)
- JARDIANCE (ORAL)
- SYNJARDY (ORAL)
- XIGDUO XR (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Sulfonylureas

Recommendations for the PDL are:

- GLIMEPIRIDE (ORAL)
- GLIPIZIDE (ORAL)
- GLIPIZIDE ER (ORAL)
- GLYBURIDE (ORAL)
- GLYBURIDE MICRONIZED (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, TZD

Recommendations for the PDL are:

- PIOGLITAZONE (ORAL)

There were no further discussions made by the committee about this class.

Immunosuppressives, Oral

Recommendations for the PDL are:

- AZATHIOPRINE (ORAL)
- CYCLOSPORINE SOFTGEL (ORAL)
- CYCLOSPORINE, MODIFIED CAPSULE (ORAL)
- MYCOPHENOLATE MOFETIL CAPSULE (ORAL)
- MYCOPHENOLATE MOFETIL TABLET (ORAL)
- MYCOPHENOLIC ACID (ORAL)
- RAPAMUNE SOLUTION (ORAL)
- RAPAMUNE TABLET (ORAL)
- SIROLIMUS SOLUTION (ORAL)
- SIROLIMUS TABLET (AG) (ORAL)
- SIROLIMUS TABLET (ORAL)
- TACROLIMUS (ORAL)

There were no further discussions made by the committee about this class.

Lincosamides/Oxazolidinones/Streptogramins

Recommendations for the PDL are:

- CLINDAMYCIN CAPSULES (ORAL)
- CLINDAMYCIN PALMITATE SOLUTION (ORAL)
- LINEZOLID TABLET (AG) (ORAL)
- LINEZOLID TABLET (ORAL)

There were no further discussions made by the committee about this class.

Lipotropics, Other

Recommendations for the PDL are:

- CHOLESTYRAMINE/SUCROSE (ORAL)
- COLESTIPOL GRANULES (ORAL)
- COLESTIPOL TABLET (ORAL)
- EZETIMIBE (ORAL)
- FENOFIBRATE CAPSULE (LOFIBRA) (ORAL)

- FENOFIBRATE TABLET (LOFIBRA) (ORAL)
- FENOFIBRATE TABLET (TRICOR) (ORAL)
- GEMFIBROZIL (ORAL)
- ICOSAPENT ETHYL (ORAL)
- NIACIN ER (ORAL)
- OMEGA-3 ACID ETHYL ESTERS (ORAL)
- PRALUENT PEN (SUBCUTANEOUS)
- REPATHA PUSHTRONEX (SUBCUTANEOUS)
- REPATHA SURECLICK (SUBCUTANEOUS)
- REPATHA SYRINGE (SUBCUTANEOUS)
- VASCEPA (ORAL)

There were no further discussions made by the committee about this class.

Lipotropics, Statins

Recommendations for the PDL are:

- ATORVASTATIN (ORAL)
- LOVASTATIN (ORAL)
- PRAVASTATIN (ORAL)
- ROSUVASTATIN (ORAL)
- SIMVASTATIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

Macrolides/Ketolides

Recommendations for the PDL are:

- AZITHROMYCIN PACKET (AG) (ORAL)
- AZITHROMYCIN SUSPENSION (ORAL)
- AZITHROMYCIN TABLET (ORAL)
- CLARITHROMYCIN TABLET (ORAL)
- ERYTHROMYCIN BASE TABLET DR (ORAL)

There were no further discussions made by the committee about this class.

Multiple Sclerosis Agents

Recommendations for the PDL are:

- AVONEX (INTRAMUSC.)
- AVONEX PEN (INTRAMUSC.)
- BETASERON KIT (SUBCUTANE.)
- COPAXONE 20 MG/ML (SUBCUTANE.)
- COPAXONE 40 MG/ML (SUBCUTANE.)
- DALFAMPRIDINE ER (ORAL)

- DIMETHYL FUMARATE DR (ORAL)
- DIMETHYL FUMARATE DR STARTER PACK (ORAL)
- FINGOLIMOD (ORAL)
- GLATIRAMER 20 MG/ML (SUBCUTANE.)
- GLATIRAMER 40 MG/ML (SUBCUTANE.)
- KESIMPTA (SUBCUTANE.)
- TERIFLUNOMIDE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Nitrofurantoin Derivatives

Recommendations for the PDL are:

- NITROFURANTOIN MACROCRYSTALS CAPSULES (AG) (ORAL)
- NITROFURANTOIN MACROCRYSTALS CAPSULES (ORAL)
- NITROFURANTOIN MONO-MACRO CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Opiate Dependence Treatments

Recommendations for the PDL are:

- BRIXADI MONTHLY (SUBCUTANEOUS)
- BRIXADI WEEKLY (SUBCUTANEOUS)
- BUPRENORPHINE HCL (SUBLINGUAL)
- BUPRENORPHINE/NALOXONE FILM (SUBLINGUAL)
- BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)
- NALOXONE SPRAY (AG) (NASAL)
- NALOXONE SPRAY (NASAL)
- NALOXONE SYRINGE (INJECTION)
- NALOXONE VIAL (INJECTION)
- NALTREXONE (ORAL)
- NARCAN SPRAY (NASAL)
- OPVEE SPRAY (NASAL)
- SUBLOCADE (SUBCUTANEOUS)
- SUBOXONE FILM (SUBLINGUAL)
- VIVITROL (INTRAMUSC)
- ZUBSOLV (SUBLINGUAL)

There were no further discussions made by the committee about this class.

PAH Agents, Oral and Inhaled

Recommendations for the PDL are:

- AMBRISENTAN (ORAL)

- BOSENTAN TABLET (ORAL)
- SILDENAFIL SUSPENSION (AG) (ORAL)
- SILDENAFIL SUSPENSION (ORAL)
- SILDENAFIL TABLET (ORAL)
- TADALAFIL (ADCIRCA) (ORAL)
- TRACLEER TABLET (ORAL)

There were no further discussions made by the committee about this class.

Pancreatic Enzymes

Recommendations for the PDL are:

- CREON (ORAL)
- ZENPEP (ORAL)

There were no further discussions made by the committee about this class.

Pediatric Vitamin Preparations

Recommendations for the PDL are:

- FLUORIDE/VITAMINS A, C, AND D DROPS (ORAL)
- MULTIVITAMINS WITH FLUORIDE DROPS (ORAL)
- MULTIVITS WITH IRON & FLUORIDE DROPS (ORAL)
- PEDI MVI NO.17 WITH FLUORIDE CHEW (ORAL)

There were no further discussions made by the committee about this class.

Phosphate Binders

Recommendations for the PDL are:

- CALCIUM ACETATE CAPSULE (ORAL)
- RENVELA TABLET (ORAL)
- SEVELAMER CARBONATE TABLET (AG) (ORAL)
- SEVELAMER CARBONATE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Pituitary Suppressive Agents, LHRH

Recommendations for the PDL are:

- FENSOLVI (SUBCUTANEOUS)
- LEUPROLIDE ACETATE (SUBCUTANEOUS)
- LUPRON DEPOT (INTRAMUSC)
- LUPRON DEPOT KIT (INJECTION)
- SYNAREL (NASAL)

There were no further discussions made by the committee about this class.

Platelet Aggregation Inhibitors

Recommendations for the PDL are:

- ASPIRIN/DIPYRIDAMOLE (ORAL)
- BRILINTA (ORAL)
- CLOPIDOGREL (ORAL)
- DIPYRIDAMOLE (ORAL)
- PRASUGREL (ORAL)

There were no further discussions made by the committee about this class.

Potassium Binders

Recommendations for the PDL are:

- LOKELMA (ORAL)
- LOKELMA (UNIT DOSE) (ORAL)
- SODIUM POLYSTYRENE SULFONATE (ORAL)

There were no further discussions made by the committee about this class.

Proton Pump Inhibitors

Recommendations for the PDL are:

- ESOMEPRAZOLE SUSPENSION (ORAL)
- LANSOPRAZOLE CAPSULES (ORAL)
- NEXIUM SUSPENSION (ORAL)
- OMEPRAZOLE (ORAL)
- PANTOPRAZOLE (ORAL)
- PANTOPRAZOLE SUSPENSION (ORAL)
- PROTONIX SUSPENSION (ORAL)

There were no further discussions made by the committee about this class.

Sinus Node Inhibitors

Recommendations for the PDL are:

- Corlanor is currently the only agent in this class; it was recommended nonpreferred

There were no further discussions made by the committee about this class.

Skeletal Muscle Relaxants

Recommendations for the PDL are:

- BACLOFEN (ORAL)
- CYCLOBENZAPRINE (ORAL)
- METHOCARBAMOL (ORAL)

- TIZANIDINE TABLETS (ORAL)

There were no further discussions made by the committee about this class.

Tetracyclines

Recommendations for the PDL are:

- DOXYCYCLINE HYCLATE CAPSULE (ORAL)
- DOXYCYCLINE HYCLATE TABLET (ORAL)
- DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (AG) (ORAL)
- DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)
- DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (AG) (ORAL)
- DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)
- DOXYCYCLINE MONOHYDRATE TABLET (ORAL)
- MINOCYCLINE CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Ulcerative Colitis Agents

Recommendations for the PDL are:

- APRISO (ORAL)
- BALSALAZIDE (ORAL)
- MESALAMINE (CANASA) (AG) (RECTAL)
- MESALAMINE (CANASA) (RECTAL)
- MESALAMINE ER (APRISO) (AG) (ORAL)
- MESALAMINE ER (APRISO) (ORAL)
- SULFASALAZINE (AG) (ORAL)
- SULFASALAZINE (ORAL)
- SULFASALAZINE DR (AG) (ORAL)

There were no further discussions made by the committee about this class.

Uterine Disorder Treatments

Recommendations for the PDL are:

- MYFEMBREE (ORAL)
- ORIAHNN (ORAL)
- ORILISSA (ORAL)

There were no further discussions made by the committee about this class.

Vasodilators, Coronary

Recommendations for the PDL are:

- BIDIL (ORAL)
- ISOSORBIDE DINITRATE (ORAL)

- ISOSORBIDE DINIT/HYDRALAZINE TABLET (AG) (ORAL)
- ISOSORBIDE DINTRATE/HYDRALAZINE (ORAL)
- ISOSORBIDE MONONITRATE (ORAL)
- ISOSORBIDE MONONITRATE SR (ORAL)
- NITRO-BID OINT. (TRANSDERM)
- NITROGLYCERIN (AG) (SUBLINGUAL)
- NITROGLYCERIN (SUBLINGUAL)
- NITROGLYCERIN (AG) (TRANSDERM)
- NITROGLYCERIN (TRANSDERM)

There were no further discussions made by the committee about this class.

Hepatitis C Treatment Course

Recommendations for the PDL are:

- SOFOSBUVIR/VELPATASVIR (AG) (ORAL)
- VOSEVI (ORAL) (12 WEEKS)

There were no further discussions made by the committee about this class.

Single Drug Reviews

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Tanner Odom	Sage Therapeutics	Zuruvae
Jennifer Acosta	UCB	Bimzelx
Conner McGlavin	Takeda	Fruzaqla
Pediatric Hematologist	LSU	Gene therapy for sickle cell disease
Zachary Leblanc	Children's Hospital LSU and New Orleans	Gene therapy for sickle cell disease
Laura Finn	Ochsner	Gene therapy for sickle cell disease
Ben Watkins	Tulane	sickle cell disease
Clark Paramore		sickle cell disease
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

The single drugs were reviewed, and their recommendations are:

Anticonvulsants

Recommendations for the PDL are:

- DIVALPROEX SPRINKLE (ORAL) - recommend preferred
- RUFINAMIDE TABLET (ORAL) - recommend preferred
- RUFINAMIDE SUSPENSION (ORAL) - recommend preferred
- MOTPOLY XR (ORAL) – recommend NPD

Antidepressants, Other

Recommendations for the PDL are:

- ZURZUVAE (ORAL) - recommend NPD

Cytokine and CAM Antagonists

Recommendations for the PDL are:

- ABRILADA KIT (INJECTION) (CF) 50 MG/ ML -recommend NPD
- ABRILADA PEN KIT (INJECTION) (CF) 50 MG/ ML - recommend NPD
- ADALIMUMAB-ADBM KIT (INJECTION) (CF) 50 MG/ML -recommend NPD
- ADALIMUMAB-ADBM PEN KIT (INJECTION) (CF) 50 MG/ML - recommend NPD
- AMJEVITA KIT (INJECTION) (CF) 100 MG/ML - recommend NPD
- AMJEVITA PEN KIT (INJECTION) (CF) 100 MG/ML – recommend NPD
- BIMZELX PEN (SUBCUTANE.) – recommend NPD
- BIMZELX SYRINGE (SUBCUTANE.) – recommend NPD
- COSENTYX VIAL (INTRAVENOUS) - recommend NPD
- ENTYVIO PEN (SUBCUTANE.) - recommend NPD
- OMVOH PEN (SUBCUTANE.) - recommend NPD
- OMVOH VIAL (INJECTION) - recommend NPD
- VELSIPITY (ORAL) - recommend NPD
- YUFLYMA PEN KIT (INJECTION) (CF) 100 MG/ML - recommend NPD

Hemophilia Treatment

Recommendations for the PDL are:

- BALFAXAR (INTRAVEN) - recommend NPD

Immunomodulators, Atopic Dermatitis

Recommendations for the PDL are:

- ZORYVE FOAM (TOPICAL)- recommend NPD

Oncology, Oral – Breast

Recommendations for the PDL are:

- TRUQAP TABLET (ORAL) - recommend NPD

Oncology, Oral - Hematologic

Recommendations for the PDL are:

- OJJAARA (ORAL)- recommend NPD

Oncology, Oral – Lung

Recommendations for the PDL are:

- AUGTYRO CAPSULE (ORAL) - recommend NPD
- ROZLYTREK PELLETT PACK (ORAL) - recommend NPD
- XALKORI PELLETT (ORAL) - recommend NPD

Oncology, Oral – Other

Recommendations for the PDL are:

- FRUZAQLA (ORAL) - recommend NPD
- IWILFIN TABLET (ORAL) - recommend NPD
- OGSIVEO (ORAL) - recommend NPD

Ophthalmics, Anti-inflammatory/Immunomodulator

Recommendations for the PDL are:

- VEVYE (OPHTHALMIC) - recommend NPD

Sickle Cell Anemia

Recommendations for the PDL are:

- CASGEVY (INTRAVENOUS) - recommend NPD
- LYFGENIA (INTRAVENOUS) - recommend NPD

Other Changes

Stimulants and Related Agents

Recommendations for the PDL are:

- AMPHETAMINE SALT COMBO ER (ORAL) - recommended preferred
- AMPHETAMINE SALT COMBO ER (AG) (ORAL) - recommended preferred

Glucocorticoids, Inhaled

Recommendations for the PDL are:

- FLUTICASONE/SALMETEROL (ADVAIR) (INHALATION) - recommended preferred
- FLUTICASONE/SALMETEROL (ADVAIR) (AG) (INHALATION) - recommended preferred
- FLUTICASONE/SALMETEROL HFA (AG) (INHALATION) - recommended preferred
- BUDESONIDE/FORMOTEROL (INHALATION) - recommended preferred
- BUDESONIDE/FORMOTEROL (AG) (INHALATION) - recommended preferred

Anticonvulsants

Recommendations for the PDL are:

- CARBAMAZEPINE ER (CARBATROL) (ORAL) - recommended preferred
- CARBAMAZEPINE XR (ORAL) - recommended preferred
- DIVALPROEX SPRINKLE (ORAL) - recommended preferred
- CARBAMAZEPINE XR (AG) (ORAL) - recommended preferred
- OXCARBAZEPINE SUSPENSION (ORAL) - recommended preferred
- RUFINAMIDE SUSPENSION (ORAL) - recommended preferred
- RUFINAMIDE TABLET (ORAL) - recommended preferred
- TOPIRAMATE ER (TOKENDI) (ORAL) - recommended preferred
- VIGABATRIN TABLET (ORAL) - recommended preferred
- VIGABATRIN POWDER PACK (ORAL) - recommended preferred

Ophthalmics, Glaucoma Agents

Recommendations for the PDL are:

- BRIMONIDINE 0.15% (ALPHAGAN P 0.15%) (OPHTHALMIC) - recommended preferred
- BRIMONIDINE TARTRATE/TIMOLOL DROPS (AG) (OPHTHALMIC) - recommended preferred
- BRIMONIDINE TARTRATE/TIMOLOL DROPS (OPHTHALMIC) - recommended preferred

Immunomodulators, Atopic Dermatitis

Recommendations for the PDL are:

- PIMECROLIMUS (TOPICAL) - recommended preferred
- PIMECROLIMUS (AG) (TOPICAL) - recommended preferred

Ophthalmics, Anti-Inflammatory/Immunomodulators

Recommendations for the PDL are:

- CYCLOSPORINE (OPHTHALMIC) - recommended preferred
- CYCLOSPORINE (AG) (OPHTHALMIC) - recommended preferred

Oncology, Oral – Hematologic

Recommendations for the PDL are:

- LENALIDOMIDE (ORAL) - recommended preferred

COPD

Recommendations for the PDL are:

- TIOTROPIUM (INHALATION) - recommended preferred

Bronchodilators, Beta-Agonists

Recommendations for the PDL are:

- ALBUTEROL HFA (VENTOLIN) (AG) (INHALATION) - recommended preferred

Proposed Therapeutic Classes to be Reviewed at Next Meeting

The committee members were shown the list of therapeutic classes that will be reviewed on the fall 2024 meeting.

Next Meeting Date


The proposed date for the next P&T committee meeting is 10/25/2024 or 10/30/2024.

Other Business

Ms. Fontenot thanked all of the P&T committee members for attending and indicated they will keep trying to establish quorum.

Adjournment

The meeting adjourned at or about 11:49 am CT.



Handwritten signature and date: 10/30/24